





SYNGENE

9 December 2024


About company

Syngene International Limited is a leading contract research, development, and manufacturing organization (CRO/CDMO) based in India. It provides end-to-end solutions in discovery, development, and commercial-scale manufacturing for pharmaceuticals, biotechnology, and other industries. Established in 1993, Syngene serves global clients, including major pharmaceutical companies. Its expertise spans diverse domains, including small molecules, biologics, and specialty chemicals.

Financials



MARKET CAP	₹ 35,302 Cr.
P/E RATIO	76.6
DIVIDEND YIELD	0.14%
ROCE	14.7%
ROE	13.2%
FACE VALUE	10.00
3 YEARS SALES GROWTH	17%
3 YEARS PROFIT GROWTH	11%



Our recommendation

OPTION INSIGHT: BUY SYNGENE 870 PUT ABOVE 18.50 TARGET 23.50/28.50 STOPLOSS BELOW 13.50

Technical analysis

Syngene International Ltd share prices opened huge gap down and the prices are sustaining at lower level. With no potential signs of bouncing back, the stock is likely to continue its bearish trend for a while as it is continuously trading below its 20 EMA level. Supertrend indicator is showing bearish trend as red zone is active in it (as shown in image below). The prices are expected to retest its lower level near 860 with 900 still remain as the key resistance area. Thus, we recommend SYNGENE 870 PUT options.

rumpusroom published on TradingView.com, Dec 10, 2024 16:22 UTC+5:30



Disclaimer

I, Ruchi Nahar, SEBI Registered Research Analyst (INH000014544) comply with the qualification and certification requirements under SEBI (Research Analyst) Regulations, 2014. I have qualified CA, CS and MBA, has over 11 years of experience in MNCs, culminating as Head of Finance. I now leverage my expertise to guide stock market investors with strategic insights. All of the views expressed in research reports and recommendations issued by me reflect my personal views about the subject company or companies at the given point of time and I do not receive/accept any kind of compensation, directly or indirectly related to specific recommendations or views expressed in reports issued by me. I/my relatives do not at any point of time of issuing the reports have any material conflict of interest in the subject company neither I was/am/will be engaged in market making activity for the subject company. The investments discussed or views expressed in reports and recommendations issued by me may not be suitable for all investors. The user assumes the entire risk of any use made of this information. I nor any person connected with my report, accepts any liability arising from the use of research document. The recipients of research document should rely on their own investigations and should consult their own financial advisors to determine merit and risks of such investments based on their own risk appetite. Price and value of the investments referred to in this material may go up or down. Past performance is not a guide for future performance. Certain transactions including those involving futures, options and other derivatives as well as non-investment grade securities involve substantial risk and are not suitable for all investors. Reports and recommendations based on technical analysis centres on studying charts of a stock's price movement and trading volume, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals. Opinions expressed in research reports & recommendations will be based on the current opinions as of the date appearing in research report & recommendations. While I endeavour to update on a reasonable basis the information discussed in research reports, there may be regulatory, compliance, or other reasons that prevent me from doing so. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice. So far as reports include current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed. Investment in securities market is subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

9 December 2024

